Sometimes initial phase 1/1b readouts at cancer conferences produce quite different reactions from a live and remote audience while at other meetings, the Developmental Therapeutics talks produce little or no interest at all. It’s often hard to guage which way they will go.
At SITC this weekend, several talks generated some contentious, and at times quite heated, debate and intense interest.
One of these was an oral presentation by Dr Zev Wainberg on the first-in-man data with the anti-CSF1R and anti-PD1 inhibitors, cabiralizumab and nivolumab, from Five Prime and BMS respectively, in an advanced pancreatic cohort.
Dr Zev Wainberg at SITC 2017
There was a surprising amount of confusion surrounding the initial results and other issues last week, with Five Prime’s stock dropping before we’d even got to Dr Wainberg’s talk.
What became increasingly obvious over the weekend was a clear difference in investors perceptions versus what the scientific community actually thought.
Here we take a look at the data and explain what to watch out for and why…
To learn more insights on our latest conference coverage, subscribers can log-in or you can click to gain access to BSB Premium Content.
At the 2016 San Antonio Breast Cancer Symposium (SABCS16), I had the great pleasure to talk with a leading inflammatory breast cancer expert and translational researcher, Naoto T. Ueno MD PhD.
Dr Naoto Ueno at SABCS16
Dr Ueno is Executive Director of the Morgan Welch Inflammatory Breast Cancer Research Program and Clinic at the University of Texas MD Anderson Cancer Center.
He’s active on Twitter where, as @teamoncology, he shares information on the latest developments in breast cancer, often writing in Japanese for his followers.
A cancer survivor himself, he also brings an empathy to patient care through his own treatment experience.
Anyone who follows him on Twitter, will also know he is a “foodie.” Prior to our chat, I joked he should write the definitive guide to San Antonio restaurants for attendees… he definitely ate better than I did at the meeting!
MD Anderson also has an IBC conference coming up next month for those interested in the area:
What caught my attention at SABCS16 were posters from MD Anderson researchers that offered insight into the challenges and opportunities in targeting this rare form of breast cancer, something we don’t hear a lot about.
If you have a keen interest in IBC, do follow @teamoncology – if you don’t already!
We spend a lot of time in the poster halls at scientific and medical meetings such as European Society for Medical Oncology (ESMO) Congress in Madrid because that’s where the action is in terms of finding nuggets of promising preclinical and early clinical data. You can also spot new trends emerging earlier this way.
At large meetings run by the American Society of Hematology (ASH) and American Association for Research (AACR) there are literally thousands of posters, all of which have passed the grade to merit presentation.
Gaining insights from posters, and in particular, picking those that really matter is often an art rather than a science – a lot of intuition is involved.
This post discusses a few of the posters presented in the developmental therapeutic session at ESMO this year. It focuses on non-immunotherapy topics, i.e. traditional TKIs and monoclonal antibodies to specific mutations or other targets.
Subscribers can login to read more. Do consider supporting our cancer conference coverage by becoming a subscriber.
Thanks for your support!